ADVANCED MALIGNANT SOLID TUMORS
Clinical trials for ADVANCED MALIGNANT SOLID TUMORS explained in plain language.
Never miss a new study
Get alerted when new ADVANCED MALIGNANT SOLID TUMORS trials appear
Sign up with your email to follow new studies for ADVANCED MALIGNANT SOLID TUMORS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug JSKN022 enters human testing for tough cancers
Disease control Recruiting nowThis early-phase study is testing a new drug called JSKN022 in 225 adults with advanced solid tumors that have stopped responding to standard treatments. The main goal is to check the drug's safety and find the best dose. Researchers will also look for early signs that the drug c…
Matched conditions: ADVANCED MALIGNANT SOLID TUMORS
Phase: PHASE1 • Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd • Aim: Disease control
Last updated May 26, 2026 07:48 UTC
-
New pill shows promise in early trial for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests an experimental oral drug, CSCJC3456, in 102 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants take the p…
Matched conditions: ADVANCED MALIGNANT SOLID TUMORS
Phase: PHASE1 • Sponsor: Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 07:24 UTC
-
New drug combo aims to shrink hard-to-treat cancers
Disease control Recruiting nowThis study tests two experimental drugs, JS212 and JS213, in people with advanced solid tumors that have spread or cannot be removed. The goal is to see if these drugs can shrink tumors and control the disease. About 480 adults with certain cancers like kidney, prostate, bladder,…
Matched conditions: ADVANCED MALIGNANT SOLID TUMORS
Phase: PHASE2 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated May 20, 2026 11:56 UTC
-
New combo therapy targets Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new pill (FC084CSA) combined with an immunotherapy (tislelizumab) in people with advanced solid tumors that haven't responded to standard treatments. The goal is to find the safest dose and see if the combination can shrink tumors or slow their growth. About 33…
Matched conditions: ADVANCED MALIGNANT SOLID TUMORS
Phase: PHASE1, PHASE2 • Sponsor: FindCure Biosciences (ZhongShan) Co., Ltd. • Aim: Disease control
Last updated May 13, 2026 16:03 UTC